FDA Grants Platform Tech Designation To Viral Vector In Sarepta's SRP-9003 For LGMD Type 2E/R4

Sarepta Therapeutics Inc SRPT:

• U.S. FDA GRANTS PLATFORM TECHNOLOGY DESIGNATION TO THE VIRAL VECTOR USED IN SRP-9003, SAREPTA’S INVESTIGATIONAL GENE THERAPY FOR THE TREATMENT OF LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2E/R4